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Abstract
Aim Omentectomy in addition to bariatric surgery has been
suggested to improve metabolic outcome but short-term (6–
24 months) studies have refuted this notion. We investigated
whether there was any long-term impact of omentectomy.
Methods Forty-nine obese women underwent gastric bypass
surgery and were randomly assigned to omentectomy (n = 26)
or not (n = 23). They were re-examined after 5 years including
dual-energy X-ray absorptiometry for body composition,
blood pressure and blood sampling.
Results There were no significant differences between the two
groups at baseline (p = 0.07–0.93) or 5 years post-operatively
(p = 0.15–0.93) regarding weight, BMI, body composition,
HOMA-IR, plasma cholesterol, HDL cholesterol, or
triglycerides.
Conclusion In agreement with previous shorter studies, re-
moval of the greater omentum in addition to GBP is not asso-
ciated with metabolic benefits after long-term follow-up.
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Introduction
Abdominal obesity, which reflects the amount of visceral ad-
ipose tissue, has been identified as an independent risk factor
for type 2 diabetes and cardiovascular disease [1]. The in-
creased metabolic risk of excess visceral adipose tissue is
probably due to multiple underlying mechanisms. Björntorp
described in 1990 that the portal drainage of visceral adipose
tissue to the liver results in increased levels of metabolites in
visceral obesity that may have profound effects on hepatic
metabolism [2]. In particular, non-esterified fatty acids have
been proposed to be of importance as visceral adipose tissue
displays increased lipolysis compared to subcutaneous depots
[3]. This prompted the hypothesis that removal of visceral
adipose tissue in conjunction with bariatric surgery could have
additional positive metabolic effects. The major omentum,
which constitutes a substantial portion of the visceral adipose
tissue compartment, is easily accessible during surgery. In
2002, our group published a pilot study designed as a random-
ized controlled trial in 50 subjects undergoing adjustable gas-
tric banding with or without simultaneous removal of the
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glucose tolerance and insulin sensitivity in the group under-
going omentectomy [4]. However, since then, several ran-
domized controlled trials with up to 2 years follow-up have
reported no effects of either omentectomy in addition to bar-
iatric surgery or omentectomy alone, as discussed previously
[5]. The purpose of the present study was to investigate, in a
previously described cohort [5], whether positive metabolic
effects of omentectomy together with gastric bypass could
be observed over a longer follow-up of 5 years.
Material and Methods
The inclusion and exclusion criteria, patient characteristics
before, and 2 years post-operatively have previously been
described in detail [5]. Briefly, 81 obese women scheduled
for open gastric bypass were randomized to operation with
or without removal of the greater omentum. For pre- and
post-surgical investigations, the subjects reported to the re-
search unit in the morning after an overnight fast. Height,
weight, waist circumference, and blood pressure were mea-
sured. Body composition was measured with dual-energy X-
ray absorptiometry (DEXA) using a GE-Lunar iDXA (GE
Healthcare, Madison, WI, USA). The software (enCORE ver-
sion 14.10.022) was used to determine body fat content in
different locations and also to estimate visceral adipose tissue
(EVAT) and subcutaneous adipose tissue (ESAT) depots in the
android region, as previously described and discussed [6, 7].
A blood sample was collected for subsequent analysis of glu-
cose, insulin (Insulin, ELISA, Mercodia Uppsala, Sweden),
cholesterol, high-density lipoprotein (HDL), and triglycerides.
Insulin resistance was estimated by the homeostasis model
assessment of insulin resistance (HOMA-IR). Subjects were
contacted by phone every 6 months during the first 2 years
post-operatively and were asked to report their current weight.
The study was approved by the regional ethical review board.
All participants gave their written informed consent. The sta-
tistical software JMP version 12.1.0 (SAS Institute Inc. Cary,
NC. US) was used to compare groups with unpaired t test in
per-protocol analysis. The primary endpoint 2 years post-
operatively in the randomized controlled trial was insulin sen-
sitivity measured by hyperinsulinemic euglycemic clamp and
this parameter was used for power calculation to define the
number of subjects needed to detect a clinically significant
difference between the groups [5]. In this follow-up study,
we had insulin sensitivity measured by HOMA-IR as primary
endpoint and did not perform any power calculation.
Results
Out of the 81 subjects initially included in the study, 26
omentectomized and 23 non-omentectomized completed the
follow-up examinations 5 years post-operatively. The was no
statistical difference between the subjects that were examined
after 5 years and the subjects that were lost to follow-up re-
garding baseline age, weight, BMI, glucose or insulin. As
expected, there was a significant improvement in all anthro-
pometric and metabolic parameters at 5 years after compared
to before surgery in both groups (Table 1). The average weight
of the removed omentum from the 26 omentectomized sub-
jects was 525 ± 246 g with a removed omentum weight/
baseline body weight ratio of 0.0045 ± 0.0023. There was a
significant weight regain between the 2- and 5-year follow-up
examinations (omentectomy 79 ± 15 kg to 85 ± 19 kg p = 0.02
and non-omentectomy 79 ± 15 kg to 85 ± 16 kg p = 0.0002,
but no significant difference in body weight change between
the two groups (p = 0.15). Figure 1 shows that there were no
significant changes in BMI between the groups over the study
period. In addition, there were no significant differences be-
tween the omentectomy and non-omentectomy group regard-
ing total body fat, EVAT, ESAT, fasting plasma glucose, −in-
sulin, HOMA-IR, plasma lipids, or systolic blood pressure
(Table 1. p = 0.10–0.98). A small but statistically significant
higher diastolic blood pressure was observed in the
omentectomy compared to the non-omentectomy group (see
Table 1, p = 0.03).
Discussion
This study shows that there are no long-term beneficial effects
of omentectomy in conjunction with gastric bypass operation
5 years post-operatively. To our knowledge, this constitutes
the longest follow-up time that has been reported using this
type of intervention [5].
The rationale for why a long-term follow-up of these sub-
jects was necessary is that following a rapid initial weight loss
after gastric bypass, there is often a significant weight regain
already, 1 year after the intervention [8]. In addition, even
though a majority of subjects experience remission of type 2
diabetes initially, a relapse in diabetes can sometimes be seen
over time and it is possible that increased amounts of visceral
adipose tissue could play a role in this [8]. However, our
present data, demonstrating that omentectomy does not pro-
vide long-term benefits, suggest that diabetes relapse may
depend on other mechanisms.
The reason for why removal of a large proportion of the
visceral adipose tissue does not lead to positive metabolic
effects have been discussed previously [5]. Most importantly,
the potential positive effects of removing approximately
0.5 kg of adipose tissue might be concealed by the overall
much larger adipose tissue reduction following gastric bypass
operation or the average small proportion that it constitutes of
the baseline body weight (0.45%). Interestingly, 5 years post-
operatively, there was no significant difference in EVAT
1116 OBES SURG (2017) 27:1115–1118
between the omentectomy group and non-omentectomy
group. This can also be an explanation why there is no differ-
ence in metabolic parameters between the groups. Admittedly,
a limitation regarding this observation is that our measurement
of visceral adipose tissue is an estimation based on calcula-
tions made from DEXA examinations, and although this
Table 1 Clinical characteristics.
Values are mean ± SD. Analyzed
with unpaired t test. Baseline
characteristics have previously










N 41 40 23 26
Age (years) 41 ± 9 43 ± 9 0.42 48 ± 10 49 ± 9 0.72
Weight (kg) 119 ± 16 121 ± 15 0.52 85 ± 16 85 ± 19 0.94
BMI (kg/m2) 43.1 ± 5.4 44.3 ± 4.7 0.27 30.7 ± 5.2 31.4 ± 6.0 0.67
Waist to hip ratio 1.00 ± 0.07 1.00 ± 0.06 0.64 0.93 ± 0.07 0.92 ± 0.08 0.85
Total body fat % 53 ± 4 54 ± 3 0.41 43 ± 7 43 ± 8 0.93
Estimated visceral
adipose tissue (kg)




3.93 ± 1.00 3.89 ± 1.39 0.90 2.07 ± 1.07 2.35 ± 1.34 0.41
Systolic blood pressure
(mmHg)
133 ± 17 137 ± 17 0.23 125 ± 14 134 ± 22 0.09
Diastolic blood
pressure (mmHg)
84 ± 9 85 ± 8 0.67 76 ± 9 82 ± 10 0.03
P-glucose (mmol/L) 5.5 ± 1.1 5.6 ± 1.3 0.77 5.0 ± 0.7 5.0 ± 0.6 0.82
P-insulin (mU/l) 14.7 ± 7.5 18.2 ± 9.4 0.07 5.2 ± 2.4 6.2 ± 2.8 0.15
P-cholesterol (mmol/l) 4.8 ± 0.9 4.9 ± 0.9 0.62 4.2 ± 0.9 4.3 ± 0.8 0.73
P-HDL cholesterol
(mmol/l)
1.1 ± 0.2 1.2 ± 0.3 0.55 1.6 ± 0.4 1.6 ± 0.5 0.57
P-triglycerides
(mmol/l)
1.5 ± 0.7 1.5 ± 0.7 0.93 1.0 ± 0.6 0.9 ± 0.3 0.65
P-NEFA (mmol/l) 0.75 ± 0.24 0.81 ± 0.17 0.22 0.6 ± 0.3 0.7 ± 0.3 0.52
P-apolipoprotein B
(g/l)
0.91 ± 0.23 0.97 ± 0.25 0.28 0.82 ± 0.22 0.83 ± 0.22 0.83
P-apolipoprotein A1
(g/l)
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Fig. 1 BMI development
following bariatric surgery with
or without omentectomy. Values
before surgery and during the first
2 years post-operatively have
been published previously [5].
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estimation is a valid measure of visceral adipose tissue [9], it
has to our knowledge never been validated in subjects that
have undergone omentectomy. An additional weakness is
that the present study population size was based on a
follow-up from a previous study and not based on a power
calculation. However, no statistically beneficial changes
were found with omentectomy, and we consider that, even
if a larger study might find statistically significant changes
between the groups, there would probably not be any clini-
cally significant beneficial changes in the omentectomy
group.
In conclusion, omentectomy in conjunction with gastric
bypass operation does not confer any positive effects on
weight, insulin sensitivity, blood lipids, or blood pressure over
a long period of time. With the present study and previous
studies in mind, the relevance of omentectomy has been def-
initely addressed.
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